COMMUNIQUÉS West-GlobeNewswire

Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025
12/03/2025
Meet with Indaptus Therapeutics’ CEO Jeffrey Meckler Register at INDP-KEYS.TribePublic.com NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) announces that Indaptus’ CEO, Jeffrey [...]
Tarsus Announces Proposed $100.0 Million Public Offering
12/03/2025
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0 million of shares [...]
Anika Reports Fourth Quarter and Full Year 2024 Financial Results
12/03/2025
Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel [...]
Solésence Launches New Investor Relations Website
12/03/2025
ROMEOVILLE, Ill., March 12, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced the launch of its [...]
Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing
12/03/2025
PURCHASE N.Y., March 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition [...]
electroCore Announces Full Year 2024 Financial Results
12/03/2025
Record f ull year 2024 net sales of $ 25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCore TM in the United States Department of Veteran Affairs and United [...]
Assertio Reports Fourth Quarter and Full Year 2024 Financial Results
12/03/2025
Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Operations of $26.4 [...]
BeautyHealth Reports Full Year and Fourth Quarter 2024 Financial Results
12/03/2025
Delivers fourth quarter and full year net sales of $83.5 million and $334.3 million LONG BEACH, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth”), home to flagship [...]
Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
12/03/2025
- Interim results from three trials exploring the use of Alpha DaRT ® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile - - [...]
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
12/03/2025
SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and [...]
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025
12/03/2025
Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company [...]
Kalaris and AlloVir Announce Stockholder Approval of Merger
12/03/2025
Combined company expected to trade on Nasdaq under “KLRS” after closing PALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (“Kalaris”), a clinical-stage [...]
Xenon to Present at Stifel 2025 Virtual CNS Forum
12/03/2025
VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering [...]
Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025
12/03/2025
HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will [...]
Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025
12/03/2025
JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of [...]
aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine
12/03/2025
Peer-reviewed publication validates efzofitimod’s unique anti-inflammatory mechanism of action on macrophages through neuropilin-2 (NRP2) receptor. Scientific insights further strengthen the rationale for clinical [...]
ACTG Presents Study at CROI Demonstrating Potential of CMV-specific Antiviral Inhibitor to Improve Aging-Related Outcomes among People Living with HIV and CMV (Cytomegalovirus)
12/03/2025
LOS ANGELES, March 12, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented promising findings from a study exploring how treating asymptomatic [...]
ACTG Presents Important Findings from REPRIEVE at CROI 2025
12/03/2025
Presentations Address Frailty, Inflammation, Asymptomatic Heart Muscle Damage, and Mental Function LOS ANGELES, March 12, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other [...]
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
12/03/2025
Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]

Pages